Core Viewpoint - The Supreme Court has questioned the Securities and Exchange Board of India (Sebi) for not closing proceedings against former directors of Sterling Biotech (SBL) despite a previous court order quashing all pending criminal cases after the directors paid ₹5,100 crore as part of a settlement [4]. Group 1: Legal Proceedings - The Supreme Court had previously agreed to quash all criminal proceedings against the Sandesara brothers, contingent upon their payment of ₹5,100 crore, which is one-third of the dues owed in a bank fraud case [4]. - The court has instructed that the money deposited by the Sandesara brothers be transferred to the banks involved, and has scheduled a further hearing for the following Monday [4]. Group 2: Sebi Investigation - The Sebi investigation pertains to allegations that the Sandesara brothers secured loans from foreign banks and funneled these funds into their company as purported investments, raising concerns about potential misrepresentation to investors [3][4]. - The counsel for the Sandesara brothers indicated that Sebi has not closed its investigation despite compliance with the Supreme Court's order regarding the one-time settlement [4].